Aravive, Inc. (ARAV)

NASDAQ: ARAV · IEX Real-Time Price · USD
2.04
-0.17 (-7.69%)
Jan 26, 2022 4:00 PM EST - Market closed

Company Description

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases.

Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers.

The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau.

The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Aravive, Inc.
Aravive Logo
CountryUnited States
IPO DateMar 21, 2014
IndustryBiotechnology
SectorHealth Care
Employees17
CEOGail McIntyre

Contact Details

Address:
River Oaks Tower
Houston, Texas 77098
United States
Phone936 355 1910
Websitearavive.com

Stock Details

Ticker SymbolARAV
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001513818

Key Executives

NamePosition
Dr. Fredric N. Eshelman Pharm.D.Executive Chairman
Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.President, Chief Executive Officer and Director
Vinay Shah MBAChief Financial Officer
Dr. Reshma Rangwala M.D., Ph.D.Chief Medical Officer
Dr. Jeffrey L. ClelandCo-Founder
Dr. Joshua Silverman Ph.D.Co-Founder
Joseph T. SchepersVice President of Investor Relations
Dr. Randy L. AndersonSenior Vice President of Data Sciences
Kenneth L. GuernseySecretary

Latest SEC Filings

DateTypeTitle
Jan 19, 2022424B3Prospectus [Rule 424(b)(3)]
Jan 19, 2022EFFECTNotice of Effectiveness
Jan 5, 2022SC 13D/AGeneral statement of acquisition of beneficial ownership
Jan 5, 20224Statement of changes in beneficial ownership of securities
Jan 5, 2022S-3Registration statement under Securities Act of 1933
Jan 4, 20228-KCurrent report
Dec 23, 20214Statement of changes in beneficial ownership of securities
Dec 2, 20214Statement of changes in beneficial ownership of securities
Nov 12, 20218-KCurrent report
Nov 9, 20218-KCurrent report
View All SEC Filings